U.S. Retail Distributors Stock News

NYSE:MNR
NYSE:MNROil and Gas

A Look At Mach Natural Resources (MNR) Valuation As Higher Cash Distribution Signals Confidence

Dividend move puts Mach Natural Resources in focus Mach Natural Resources (MNR) drew the attention of income-focused investors after its board declared a fourth quarter 2025 cash distribution of $0.53 per common unit, payable on March 12, 2026. See our latest analysis for Mach Natural Resources. At a last close of $13.50, Mach Natural Resources has seen its short term momentum build, with a 30 day share price return of 18.11% and year to date share price return of 20.00%, even though the 1...
NasdaqGS:LBTY.A
NasdaqGS:LBTY.ATelecom

Liberty Global (LBTY.A) Valuation Check After 2025 Profit Swing And Recent Share Price Rebound

Liberty Global (LBTY.A) is back in focus after reporting full year 2025 results, with sales of US$4,878.5 million and a net loss of US$7,138.1 million, reversing from net income a year earlier. See our latest analysis for Liberty Global. Investors appear to be reassessing Liberty Global after the earnings release, with a 1-day share price return of 2.47% and a 7-day share price return of 18.00% on the way to a 1-year total shareholder return of 13.02%. This suggests recent momentum has picked...
NasdaqGS:GTLB
NasdaqGS:GTLBSoftware

Is It Time To Revisit GitLab (GTLB) After The Sharp Share Price Pullback?

If you are wondering whether GitLab's current share price reflects its real worth, you are not alone. This article is all about unpacking what the numbers suggest about value. GitLab shares last closed at US$24.03, after returns of an 18.7% decline over 7 days, a 33.9% decline over 30 days, a 33.6% decline year to date, and a 61.4% decline over the past year, with a 45.0% decline over 3 years. Recent coverage around GitLab has focused on its position within the software sector and how...
NYSE:ABBV
NYSE:ABBVBiotechs

The Bull Case For AbbVie (ABBV) Could Change Following Its New AI-Driven US Manufacturing And CLL Win

In recent days, AbbVie announced a US$380 million plan to build two AI-enabled active pharmaceutical ingredient facilities in North Chicago and secured US FDA approval for an all-oral, fixed-duration VENCLEXTA plus acalabrutinib regimen for previously untreated chronic lymphocytic leukemia patients. Together, these moves highlight AbbVie’s push to deepen its oncology footprint while scaling future neuroscience and obesity drug production within its US manufacturing base. We’ll now examine...
NasdaqGS:GSAT
NasdaqGS:GSATTelecom

How Investors Are Reacting To Globalstar (GSAT) Joining Virewirx’s US$1.9 Million 5G System Contract

Virewirx previously announced a US$1.9 million Phase II contract to develop an advanced 5G system, naming Globalstar as a key technology collaborator, while Globalstar also scheduled its fourth-quarter 2025 earnings release for February 27 before the market opened. This pairing of a specialized 5G collaboration with ongoing satellite and network investments highlights how Globalstar is pushing deeper into complex hybrid connectivity solutions. We’ll now examine how Globalstar’s role in...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

Is BioCryst Pharmaceuticals (BCRX) Offering Long-Term Value After Recent Share Price Swings

If you are wondering whether BioCryst Pharmaceuticals is attractively priced at its recent share price of US$7.58, you are not alone. This article will focus on what that number might really represent for long term investors. The stock has recently shown mixed momentum, with a 12.1% move over the past 7 days and 11.6% over 30 days, while the 1 year return sits at a decline of 8.6% and the 5 year return at a decline of 36.7%. These moves come against a backdrop of ongoing market attention on...
NasdaqGS:GTX
NasdaqGS:GTXAuto Components

Garrett Motion Expands Beyond Turbochargers With Zero Emission And Industrial Wins

Garrett Motion (NasdaqGS:GTX) announced new partnerships and product awards in zero emission mobility and industrial applications. The company secured a major serial award for its oil free centrifugal compressor with Cling for electric commercial vehicles in China. Garrett also launched the commercial debut of its MEG turbocharger with Weichai for marine and power generation uses. Garrett Motion, trading at $19.28, has seen its share price move 10.9% higher year to date and 103.3% over the...
NasdaqGS:COST
NasdaqGS:COSTConsumer Retailing

Is Costco (COST) Still Attractive After Near Four Figure Share Price And Mixed Returns

If you are wondering whether Costco Wholesale's near four-figure share price still offers value, you are not alone. This article is designed to help you frame that question clearly. The stock last closed at US$986.02, with returns of a 3.2% decline over the past 7 days, 0.3% over 30 days, 15.4% year to date, a 4.3% decline over 1 year, 110.9% over 3 years and 213.9% over 5 years. Recent coverage has focused on Costco's consistent membership model, its large-scale warehouse footprint and its...
NYSE:AMT
NYSE:AMTSpecialized REITs

American Tower Insider Sales And Buyback Put Capital Decisions In Focus

American Tower (NYSE:AMT) recently completed a $365 million share buyback program. The company's CFO executed significant insider selling around the same period, drawing extra attention to management's actions. American Tower appointed a new chief accounting officer, marking a meaningful change in its finance leadership team. American Tower, trading at $190.05 at last close, is in the spotlight as investors weigh these moves together rather than in isolation. The stock is up 6.3% over the...
NYSE:ALB
NYSE:ALBChemicals

Albemarle (ALB) Valuation Check As Lithium Recovery Hopes And Cost Cuts Follow Plant Idle Decision

Albemarle (ALB) is back in focus after management moved to idle its Kemerton lithium hydroxide plant in Western Australia, while guiding to flat 2026 volumes and aiming for higher profitability as lithium prices recover. See our latest analysis for Albemarle. The Kemerton announcement and 2026 guidance landed after a period of sharp share price moves, with Albemarle up 5.40% on a 1 day share price return and 41.72% over 90 days. The 1 year total shareholder return of 123.63% contrasts with a...
NYSE:HCA
NYSE:HCAHealthcare

Will AI Optimism and New Capacity Expansion Shift HCA Healthcare's (HCA) Risk‑Reward Narrative?

HCA Healthcare recently featured at the ViVE 2026 conference in Los Angeles while expanding its footprint with new facilities in Florida, Texas, and Utah and holding weekly “Talent Thursdays” hiring events ahead of the HCA Florida Gainesville Hospital opening in May 2026. Together with broadened analyst optimism around artificial intelligence and potential Medicaid supplemental payment updates, these moves highlight how HCA is leaning into technology and physical capacity expansion to...
NYSE:DK
NYSE:DKOil and Gas

A Look At Delek US Holdings (DK) Valuation After Recent Annual Loss And Revenue Update

Delek US Holdings (DK) has been drawing attention after reporting annual revenue of US$10.67b alongside a net loss of US$541.2m. This combination is putting both its refining operations and valuation under closer investor scrutiny. See our latest analysis for Delek US Holdings. The latest results land as Delek US Holdings’ share price sits at US$33.25, with a 17.82% 1 month share price return but a 13.05% 3 month share price decline. The 1 year total shareholder return of 113.50% points to...
NasdaqCM:QMMM
NasdaqCM:QMMMMedia

Assessing QMMM Holdings (QMMM) Valuation After Sharp Share Price Momentum

What recent returns say about QMMM Holdings (QMMM) QMMM Holdings (QMMM) has attracted attention after a 19.4% one day move, a return of 19.4% over the past 3 months, and a year to date gain of 87.44%. See our latest analysis for QMMM Holdings. That surge in the 1 day share price return and the latest share price of $119.4 comes on top of a 90 day share price return of 19.4% and a very large year to date share price gain. The 1 year total shareholder return is also very large, suggesting...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck Reorganizes Human Health To Shape Life After Keytruda

Merck (NYSE:MRK) is restructuring its Human Health division into two units: Oncology and Specialty, Pharma & Infectious Diseases. The company has announced new executive appointments to lead each unit as part of this reorganization. The move is intended to sharpen focus on cancer care and the broader portfolio ahead of Keytruda patent expiration. With a current share price of $123.82, Merck comes into this reorganization after a strong run, with the stock up 14.5% over the past 30 days and...
NYSE:EW
NYSE:EWMedical Equipment

Edwards Lifesciences Expands Atrial Fibrillation Reach With 2026 Product Launch

Edwards Lifesciences, ticker NYSE:EW, plans to launch new left atrial appendage closure products in 2026. The products will build on the company’s existing surgical franchise to enter a growing treatment segment for atrial fibrillation patients. The move broadens Edwards Lifesciences’ portfolio beyond its core offerings in structural heart therapies. Edwards Lifesciences, trading at $82.44, is preparing to extend its reach with new left atrial appendage closure devices that sit alongside...
NasdaqGS:TTMI
NasdaqGS:TTMIElectronic

TTM Technologies (TTMI) Is Up 16.4% After Earnings Beat, Outlook Hike And Tariff Relief - Has The Bull Case Changed?

In recent weeks, TTM Technologies reported an exceptionally strong fourth quarter with 19% year‑over‑year sales growth, raised its outlook, and gained relief from the U.S. Supreme Court’s decision to strike down global tariffs that had pressured its costs. At the same time, TTM has been highlighted as a key supplier for AI‑driven data center buildouts and defense programs, attracting fresh institutional interest from Metavasi Capital and reinforcing its role at the center of high‑reliability...
NYSE:HP
NYSE:HPEnergy Services

Is It Time To Reassess Helmerich & Payne (HP) After Its Strong 1 Year Share Price Run?

If you are wondering whether Helmerich & Payne at around US$35.13 is offering good value today, you are not alone. This article will walk through what the current market price might be implying. The stock has seen returns of 5.8% over the past week, 8.8% over the last 30 days, 17.3% year to date and 32.8% over the past year, while the 3 year return is a 4.0% decline and the 5 year return is 43.5%. Recent price moves sit against a backdrop of ongoing interest in energy and drilling companies,...
NYSE:ANF
NYSE:ANFSpecialty Retail

Abercrombie Expands To Baby And Toddler Market As Valuation Lags

Abercrombie & Fitch (NYSE:ANF) has launched an Abercrombie Kids Baby & Toddler Collection, entering the baby and toddler apparel market. The new collection extends the brand’s reach to younger children and aims to make Abercrombie a broader destination for family shopping. Abercrombie & Fitch, trading at $92.61, is adding a fresh product category at a time when its longer term share price move has been very large over the past 5 years. The stock’s shorter term performance has been mixed,...
NasdaqGS:ICFI
NasdaqGS:ICFIProfessional Services

Did Florida’s Expanded Management Services Award Just Reposition ICF International’s (ICFI) Public-Sector Playbook?

In February 2026, the Florida Department of Management Services selected ICF International as an awardee on its expanded three-year comprehensive management services contract, making the firm eligible to support statewide programs across all service categories, including disaster recovery, grants and program management, environmental and infrastructure support, workforce development, and technology modernization. A distinctive aspect of this award is Florida’s ability to tap both ICF’s...
NYSE:NET
NYSE:NETIT

Cloudflare (NET) Is Down 18.2% After Post-Quantum SASE Launch And Mastercard Deal - Has The Bull Case Changed?

In February 2026, Cloudflare announced it had completed what it calls the world’s first full Secure Access Service Edge platform with post-quantum encryption across Cloudflare One, while also reporting 2025 results showing US$614.51 million in fourth-quarter revenue and US$2.17 billion in full-year revenue alongside a continued net loss. By extending post-quantum protection to wide-area networking and partnering with Mastercard on attack-surface monitoring, Cloudflare is tying its growth...
NasdaqGS:CVBF
NasdaqGS:CVBFBanks

A Look At CVB Financial (CVBF) Valuation After Mixed Share Price Momentum

CVB Financial (CVBF) has drawn investor attention after recent share price pressure, with the stock showing negative returns over the past week, month, and past 3 months despite a modest gain year to date. See our latest analysis for CVB Financial. The recent 1 day share price return of 4.79% and 7 day share price return of 5.11% add to a softer 90 day share price return of 3.56%. At the same time, the year to date share price return of 4.45% alongside a 1 year total shareholder return of...
NYSE:TME
NYSE:TMEEntertainment

Tencent Music Entertainment (TME) Valuation Check After Recent Share Price Weakness

Recent performance snapshot Tencent Music Entertainment Group (TME) has been drawing attention after recent share price moves, with the stock closing at $14.71 and showing mixed returns over the past year and multi year periods. Short term performance has been weak, with a 1 day return of a 3.2% decline, about a 7.2% decline over the past week, and a 1 month return of a 12.4% decline. Over the past 3 months, the stock is down 20.1%, while year to date it is down 17.6%. Over longer horizons,...
NYSE:LOW
NYSE:LOWSpecialty Retail

Lowe’s Job Cuts And Refund Policy Put Store Experience In Focus

Lowe's Companies (NYSE:LOW) is cutting about 600 corporate and support roles as it reallocates resources toward store operations and customer facing activities. The company says the reductions are aimed at refocusing spending and talent on its retail footprint and in store execution. Separately, Lowe's drew attention after a customer was asked to sign a confidentiality agreement to receive a product refund. The confidentiality incident has raised questions about how the retailer handles...
NasdaqGS:GOSS
NasdaqGS:GOSSBiotechs

A Look At Gossamer Bio (GOSS) Valuation As PROSERA Phase 3 Seralutinib Results Shape Next Steps

Why Gossamer Bio’s PROSERA readout matters now Gossamer Bio (GOSS) has drawn fresh attention after releasing topline Phase 3 PROSERA data for seralutinib in pulmonary arterial hypertension and scheduling a special call to review the results and potential next steps with regulators. See our latest analysis for Gossamer Bio. The unveiling of the PROSERA Phase 3 topline data and the planned FDA discussions come after a sharp reset in sentiment, with a 30 day share price return of 84.32% decline...